AMSP Junior Scholar Outline

Alisa B. Busch, M.D., MS.

September 17, 2005

 

Alcohol and Drug Dependence: Comparisons to Other Chronic Medical Disorders

[SLIDE 1]

 

I.                    Introduction                                       

A.    What constitutes a medical disease or illness?                        [SLIDE 2]

1.      Characteristics(1)

a)      Clinical signs/symptoms

b)      Pathologic Process

c)      Etiology

i.   Influenced by family history

ii. Influenced by environmental exposure

2.      Will demonstrate in this lecture how all apply to dependence as well and that dependence is chronic medical illness.

 

B.     Common misconceptions why alcohol/drug dependence are not chronic, medical conditions.                                                                        [SLIDE 3]

1.      Dependence is a behavior, not an illness.

a)      It is volitional, not involuntary.

b)      No one is forced to drink/use drugs;  can stop if they want to.

2.      While dependence has volitional component, so do other chronic medical conditions.  Also, like other chronic medical conditions, dependence has

a)      genetic component

b)      defined pathophysiology in brain

c)      is affected (both onset and prognosis) by personal choice and culture.

C.    This lecture reviews                                                                        [SLIDE 4]

1.      Importance of identifying and treating alcohol/drug dependence.

2.      Definition.

3.      Barriers to identification and treatment of substance use disorders (SUD).

4.      Comparisons of dependence vs. other chronic medical disorders

            a) Heritability

b) Pathophysiology

            c) Individual behaviors/cultural influences

            d) Treatment goals/strategies

e) Treatment adherence

f) Outcomes

5.      Implications of treating dependence as a chronic medical condition.

 

II.                 Importance of identifying and treating alcohol/drug dependence.

A.    Epidemiology                                                                                     [SLIDE 5]

1.      Abuse/Dependence

a)      2003 national survey(2): 21.6 million persons current SUD in U.S.

i. Alcohol 15 million

ii. Illicit drugs 4 million

iii. Both 3 million

b)      90% in need did not receive treatment(2)

2.      Other chronic medical conditions

a)      Diabetes: 18.2 million people (2002 national survey)(3)

b)      HIV/AIDS: 950,000 people(year 2000 national estimate) (4)

3.      2004 U.S. Census: 293,655,404(5)

 

B.     Annual U.S. treatment costs $155 billion.                                      [SLIDE 6]

C.    Examples of medical sequelae(6-8)                                                 [SLIDE 7]           

1.      Cardiovascular

a)      Alcohol: hypertension, cardiomyopathy, MI.

b)      Cocaine: MI, cardiac arrthymias.

c)      Methamphetamine: hypertension, arrhythmia or heart failure.

d)      IV use: endocarditis.

2.      Gastrointestinal system

a)      Alcohol: Mallory Weiss tear, gastric bleeding, fatty liver, cirrhosis.

b)      IVDU: Hepatitis B and C.

3.      Neurological

a)      Alcohol--Korsakoff’s and Wernicke’s syndrome (opthalmoplegia, ataxia, and encephalopathy), peripheral neuropathy, cerebellar degeneration, cognitive deficits.

b)      Opioids—peripheral neuropathy.

c)      Cocaine—seizures, hemorrhagic stroke, subarachnoid hemorrhage.

d)      Amphetamine—stroke, subarachnoid hemorrhage.

4.      Reproductive function

a)      Alcohol—low sperm count, testicular atrophy; amenorrhea, infertility, spontaneous abortion, fetal alcohol syndrome.

b)      Cocaine—impotence: amenorrhea, fetal congenital malformations.

D. Lost productivity, unemployment, lost/cut back work days.            [SLIDE 8]

1. Heavy drinking → ↑ unemployment; ↑ lateness; ↑injury; ↓ weeks of employment; and ↓ performance.(9, 10)

2. Problem drinking à ↓ probability of working.(11)

3. Heroin use à ↓ productivity by $12 million in 1996.(12)

E. Family impacts                 

5.      Premature death.

6.      ↓ Earnings.

7.      Emotional stressors.

 

III.               Diagnosis                                            [SLIDE 9]

A.    Clinical interview key in making diagnosis.

B.     Definitions of dependence across diagnostic systems (i.e., ICD-10 and DSM-IV) reliable.(13)

C.    No laboratory tests available but (like diabetes) such tests supplement information from interviews.           

1.      Alcohol: liver function tests (AST/ALT, GGT), ↑ MCV, ↑CDT

2.  Intravenous Drug Use (IVDU): Hepatitis B and C.

D.    Definitions(14)                                                                         [SLIDE10]

1.      Abuse                                                      [SLIDE 11]

a)      Maladaptive pattern of use

b)      Causing impairment

c)       ≥ 1 within 12 month period

i.         Inability to fulfill major roles.

ii.       Use in physically hazardous situations

iii. Legal problems

iv. Continued use despite social/interpersonal problems

d)      Dependence never met

2.      Dependence                                                      [SLIDE 12]

a)      Maladaptive pattern of use

b)      Causing impairment

c)      ≥ 3 within 12 months

i.    Tolerance

a.       Need more for same effect

b.      Decreased effect with same amount used

ii.  Withdrawal

a. Withdrawal syndrome

b. Take substance to relieve/avoid withdrawal

iii. Larger amounts/longer period than intended

iv.  Persistent desire/unsuccessful efforts to cut down

v.  Much time spent getting/using/recovering

vi. Give up/reduce important social/occupational/ recreational activities

vii. Continued use despite physical/ psychological problems

 

 

IV. Barriers to identification and treatment                                                   

A.     Patients                                                                                     [SLIDE 13]

1.      2003 national survey: 95% with abuse/dependence don’t feel need treatment.(2)

2.      Stigma(15)

a)      Concern will be judged.  

b)      Prior negative experiences with doctors.

B.     Providers:                                                                                     [SLIDE 14]

1.      Biases based on personal experiences(15)

a)      Negative attitudes towards intoxication/drug use.

b) Attitudes if clinician relative has SUD: approximately 1/3 of med students.(16)

c) Personal experiences: 3.5%-9% med students have substance dependence(17)

2.       Educational barriers

a)       Medical schools/residencies inadequately educate (18)

i.         1998 survey of preclinical medical students(19)

a. 20% “no SUD training”

b. 56% “small amount”

ii.       2000 study of residencies (ER, psychiatry, primary care, and Ob-Gyn)(20)

a.  44% without required SUD training

b.  56% required only 4-15 hours of training; median of 7 hours.

b)      Clinicians don’t understand:

i.         effectiveness of identification methods and treatment(21)

ii.       what to do with the information.

3.      Clinician biases/negative attitudes; inadequate education; and stigma →  reluctance to screen(22, 23)

 

V. Is drug/alcohol dependence different from other chronic medical disorders?

[SLIDE 15]

      A. Comparison with diabetes, hypertension and asthma       

1.      Well studied conditions

2.      Effective treatments

3.      Not “curable”

B. Heritability estimates from twin studies.                                    [SLIDE 16]

1. Hypertension 25%-50%(24, 25)

2. Diabetes(26-29)

                                    a) Type I 30%-55%

                                    b) Type II 80%

                        3. Asthma 36%-70%(30, 31)

                        4. SUD(32-35)

                                    a) Heroin 34%

                                    b) Alcohol 55%

                                    c) Marijuana 52%

C. Like other medical conditions, dependence has a distinct pathophysiology.

            1.  Effects on brain circuitry                            [SLIDE 17]

a)  Alcohol/drugs either directly or indirectly acutely activate mesolimbic dopamine rich reward system(36-39)

i. Center of motivation/emotion/memory

ii Extends from ventral tegmentum to nucleus accumbens

iii. Projects to limbic system and orbitofrontal cortex

b)      Opioids/ alcohol also affect opioid and GABA receptors (36-39)

c)  Prolonged use →changes in brain function. (36, 37, 40-42)          

                                    i. Brain metabolic activity

                                    ii. Receptor availability

                                    iii. Gene expression

                                    iv. Responsiveness to environmental cues

d) Unclear if changes return to normal with abstinence(43)

2.  Changes in brain circuitry à  ↑ difficulty changing alcohol/drug behavior                                          

a) Pairing of person/places/things/specific emotions → rapid and entrenched learning/conditioning.

b) May elicit cravings. Even after long abstinence(44)     

D. Risk factors for many diseases reflect familial/genetic factors and personal choice.(45, 46)                                           

1. Familial/genetic influences                              [SLIDE 18]

a) Alcohol metabolizing enzymes impact risk of heavy drinking.(47-50)

b) Eating habits impact risk of diabetes (e.g., Native Americans).

c) Salt sensitivity can predispose to hypertension. (46)

 

2.   Personal choices                                                             [SLIDE 19]

a) Exercise influences diabetes and hypertension.

b) Foods influence both disorders.

c) Smoking impacts on diabetes, hypertension, and asthma.

d) Compliance a major problem in all conditions.

E.  Similarities in treatment.                               

1. Treatment goals(51-53)                              [SLIDE 20]

a)      Chronic medical conditions                       

i. Minimize symptoms/exacerbations.

ii. Maximize function (physical, social and role function).

iii. Treatment requires chronic care and monitoring.

            b) Alcohol/drug dependence      

i. Minimize symptoms/exacerbations.

ii. Maximize function (physical, social and role function).

iii. Treatment requires chronic care and monitoring.  But, insurance restrictions often à                                               

1) Limits on covered services

2) Emphasis on acute care, rather than ongoing treatment.

2.  Treatment strategies                              [SLIDE 21]

a) Chronic medical conditions: screening, assessment and ongoing monitoring.

b) Alcohol/drug dependence: screening, assessment and ongoing monitoring.

3. Treatment components                              [SLIDE 22]

a) Chronic medical conditions: educating patients and family members re how to control exacerbations.                                                           

i. Motivating lifestyle and behavior modification.

1) Asthma: smoking cessation, remove allergens from home (e.g., furry pets).

2) Diabetes and hypertension: smoking cessation, diet, exercise.

ii. Treating co-occurring conditions to prevent complications

1) Asthma: allergic rhinitis, GE reflux

2) Diabetes: cardiovascular and renal disease, retinopathy

3) Hypertension: cardiovascular disease, CVA.

iii. Pharmacotherapy individualized to patient needs.

1) Asthma: inhaled corticosteroids, beta-agonists

2) Diabetes: insulin preparations, oral hypoglycemic medications

3) Hypertension: ACE inhibitors, beta-blockers

b) Alcohol/drug dependence: educating patients and family members re how to control exacerbations                                                           

i.         Motivation of lifestyle and behavioral modification (e.g., discontinue use, staying away from triggers [people, places and things].

ii.       Treating co-occurring conditions/complications to prevent complications

1) Treating co-occurring psychiatric disorders

2) Treating/preventing medical sequelae.

iii.      Pharmacotherapy individualized to treatment needs.

1)      Acute detoxification

a. Alcohol: chlordiazepoxide, diazepam

b. Opioids: methadone, buprenorphine

2)      Chronic, continuing treatment

a.       Alcohol: naltrexone, acamprosate, disulfiram, topiramate (preliminary evidence)

b.      Opioids: naltrexone, methadone/buprenorphine (maintenance treatment)

c.       Cocaine: disulfiram (preliminary evidence).

iv. Core of treatments (as in asthma, diabetes, and hypertension treatment) are behavioral therapies.(54)

1) Motivational Interviewing: often brief and aimed at getting patient to accept continued treatment.

2) Relapse Prevention Therapy: focuses on process of relapse in order to prevent.

 

VI.  Does treatment work?: Comparisons between asthma/diabetes/hypertension and alcohol/drug dependence.                                

A.    What does “work” mean?                                                            [SLIDE  23]

1. Cure?—No Cure

2. Patients compliant with treatment?

3. Symptom reduction/improved functional outcomes?

B. Compliance                            [SLIDE 24]

1. Chronic Medical Conditions

a). Medications

i. Asthma 30%(55)

ii. Diabetes

a. < 60% Type I(56)

b. 36%-93% Type II.(57)

iii. Hypertension 50%-70%(58, 59)

b) Behavioral and diet modification compliance < 30%.(55, 56, 60, 61)

2. Dependence: Treatment compliance with medications and continued treatment  33-53%.(62-64)

C. Symptom reduction/functional outcomes                          [SLIDE 25]

            1. Chronic Medical Condtions

a) Type II diabetes: at 3 years follow-up inadequate glycemic control 50% with medication; 75% with diet alone.(65)

b) Asthma: adults at 1 year follow-up 10% hospitalized, 35% used ER, 35% reduced activity prior month.(66)

c) Hypertension: at 1 year follow-up > 50% inadequate blood pressure control.(67)

2.  Alcohol/drug dependence                             

a. Community treatment seeking populations: Drug Abuse Treatment Outcomes Study (DATOS)(68)                                    [SLIDE 26]           

1) 10,000 patients interviewed during treatment, 3,000 re-interviewed 1 year later; 96 programs; 11 cities across U.S.

i. Significant ↓alcohol/drug use persons in treatment < 3months

a) Heroin: long term residential (LTR)/outpatient treatment ↓ 55%

b) Cocaine: LTR/outpatient ↓ 55%

c) Marijuana: LTR ↓ 55%, outpatient ↓ 75%

d) Alcohol: LTR ↓ 35%, outpatient ↓ 65%

ii. Significant further ↓ use if in treatment ≥6 months

a) Heroin: LTR/outpatient ↓ 80%-85%

b) Cocaine: LTR/outpatient ↓ 80%-85%

c) Marijuana: LTR/outpatient ↓ 75% -80%

d) Alcohol: LTR/outpatient ↓ 75% -80%

2) Individual treatment outcomes vary depending on:

      i. severity of illness and other problems

ii. treatment appropriateness

iii. patient motivation/active engagement in treatment.

b. Non-Treatment seeking populations can also be helped.                                                                                                           

1)  4,000 persons with IVDU seeking HIV testing(69)      [SLIDE 27]

i. Randomly assigned testing alone or testing + 3 motivational interviewing sessions

ii. Intervention group improved over testing alone group at 6 months

a)  ½ rate drug injection (20% vs. 45%)

b)  4x more likely abstinent

c)  Lower arrest rates (14% vs. 24%)

2) SUD treatment in pregnant women seeking prenatal care(70)                                                 [SLIDE 28]     

i.  Case-control comparison; intervention = 1 week residential care followed by twice-weekly SUD treatment during scheduled prenatal visits

ii. Intervention group improved compared to controls at delivery

a)  Cocaine positive urines (37% vs. 63%)

b)  Higher infant birth weight

c)  Longer gestational periods

d)  Fewer infants requiring NICU admissions

e)  Shorter duration NICU admissions

f) Lower treatment costs ($14.5K vs. $46.7K)

D. Predictors of poor response/compliance                   [SLIDE 29]

1. Chronic medical conditions(55, 56, 60, 61, 71)

a) Low socioeconomic status

b) Co-occurring psychiatric conditions

c) Lack of family/social supports

2. Alcohol/Drug Dependence(54, 72, 73)

a) Low socioeconomic status

b) Co-occurring psychiatric conditions

c) Lack of family/social supports

 

VIII. Summary and implications                             

A. Drug and alcohol dependence are chronic medical conditions      [SLIDE 30]

                        1. Genetic susceptibility.

                        2. Chronic pathophysiologic and functional changes.

                        3. Risk factors influenced by familial, cultural and personal choice.

                        4. Similar rates of treatment compliance/symptom exacerbation.

                        5. Require ongoing monitoring and treatment

6. Treatment shares similar goals of improving function, decreasing exacerbations/complications.

B. Adapt strategies used in treatment of other chronic medical conditions for treatment of alcohol and drug dependence.(43)  Importance of:      [SLIDE 31]

               1. Incorporating into routine clinical care

                        a) SUD screening

                        b) Brief interventions

                        c) Patient/family education

                        d) Medical management

                        e) Referral criteria

2. Changing medical education: ↑ amount/quality of med student/resident education.                                          [SLIDE 32]

3. Changing health insurance policy: implement similar insurance coverage (parity) for SUD compared to other chronic medical conditions.

a) Enable patients to remain in continuing care/monitoring.

b) Remove limits/restrictions on number of days/visits allowed.

             

 


References:

1.            McHugh PR, Slavney PR: The Perspectives of Psychiatry. Baltimore, M.D., Johns Hopkins University Press, 1998

2.            Substance Abuse and Mental Health Services Administration: Results from the 2003 National Survey on Drug Use and Health: National Findings. Rockville, MD, SAMHSA: Office of Applied Studies, 2004

3.            American Diabetes Association: National Diabetes Fact Sheet, 2002

4.            Centers for Disease Control: Basic statistics, 2003

5.         U.S. Census Bureau: Table 1: Estimates of the residential population by selected age groups for the United States and for Puerto Rico: July 1, 2004, 2004

6.            Mendelson JH, Mello NK: Cocaine and Other Commonly Abused Drugs, in Harrison's Online Principles of Internal Medicine. Edited by Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, sselbacher KJ, McGraw Hill Companies, Inc., 2005, p Chapter 374

7.            Schuckit MA, Segal DS: Opioid Drug Abuse and Dependence, in Harrison's Online Principles of Internal Medicine. Edited by Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, sselbacher KJ, McGraw Hill Companies, Inc., 2005, p Chapter 373

8.            Schuckit MA: Alcohol and Alcoholism, in Harrison's Online Principles of Internal Medicine. Edited by Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, sselbacher KJ, McGraw Hill Companies, Inc., 2005, p Chapter 372

9.         Fisher CA, Hoffman KJ, Austin-Lane J, Kao TC: The relationship between heavy alcohol use and work productivity loss in active duty military personnel: A secondary analysis of the 1995 Department of Defense Worldwide Survey. Military Medicine 2000; 165(5):355-361

10.       Booth BM, Feng W: The impact of drinking and drinking consequences on short-term employment outcomes in at-risk drinkers in six southern states. Journal of Behavioral Health Services & Research 2002; 29(2):157-166

11.            MacDonald Z, Shields MA: Does problem drinking affect employment? Evidence from England. Health Economics 2004; 13(22):139-155

12.       Mark TL, Woody GE, Juday T, Kleber HD: The economic costs of heroin addiction in the United States. Drug & Alcohol Dependence 2001; 61(2):195-206

13.            Schuckit MA, Hesselbrock V, Tipp J: A comparison of DSM-III, DSM-IV, and ICD-10 substance use disorders diagnoses in 1992 men and women subjects in the COGA study. Addiction 1994; 89:1629-1638

14.            American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (DSM-IV-TR). Washington, D.C., American Psychiatric Association, 2000

15.            Chappel JN, Lewis DC: Medical Education:  The Aquisition of Knowledge, Attitudes, and Skills, in Substance Abuse:  A Comprehensive Textbook. Edited by Lowinson JH, Ruiz P, Millman RB, Langrod JG. Baltimore, Williams and Wilkins, 1997, pp 787-801

16.       Waller JA, Casey R: Teaching about substance abuse in medical schools. British Journal of Addiction 1990; 85:1451-1455

17.       Croen LG, Woesner M, Herman M, Reichgott M: A longitudinal study of substance use and abuse in a single class of medical students. Academic Medicine 1997; 72(5):376-381

18.       Miller NS, Sheppard LM, Colenda CC, Magen J: Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders. Academic Medicine 2001; 76(5):310-418

19.            Hoffman NG, Chang AJ, Lewis DC: Medical student attitudes toward drug addiction policy. Journal of Addictive Disorders 2000; 19:1-12

20.            Isaacson JH, Fleming M, Kraus M, al. e: A national survey of training in substance use disorders in residency programs. Journal of Studies on Alcohol 2000; 61:912-915

21.            Weisner CM, Schmidt L: Alcohol and drug problems among diverse health and social service populations. American Journal of Public Health 1993; 83:824-829

22.            Fleming MF, Barry KL: The effectiveness of alcohol screening in an ambulatory setting. Journal of Studies on Alcohol 1991; 52:33-36

23.            Friedman PD, McCullough D, Saitz R: Screening and intervention for illicit drug abuse: A national survey of primary care physicians. Archives of Internal Medicine 2001; 161(2):248-251

24.            Williams RR, Hunt SC, Hasstedt SJ, Hopkins PN, Wu LL, Berry TD, Stults BM, Barlow GK, Schumacher MC, Lifton RP, al. e: Are there interactions and relations between genetic and environmental factors predisposing to high blood pressure? Hypertension 1991; 18(suppl):129-137

25.       Fagard R, Brguljan J, Staessen J, al. e: Heritability of conventional and ambulatory blood pressure:  A study in twins. Hypertension 1995; 26:919-924

26.       Kyvik KO, Green A, Beck-Nielsen H: Concordance rates of insulin dependent diabetes mellitus. British Medical Journal 1995; 311:913-917

27.            Redondo MJ, Yu L, Hawa M, al. e: Heterogeneity of Type I diabetes:  Analysis of monozygotic twins in Great Britain and the United States. Dibetologia 2001; 44:354-362

28.       Hawa M, Rowe R, Lan MS, al. e: Value of antibodies to islet protein  tyrosine phosphatase-like molecule in predicting type I diabetes. Diabetes 1997; 46:1270-1275

29.       Kaprio J, Tuomilehto J, Koskenvuo M, Romanov K, Reunanen A, Eriksson J, Stengard J, Kesaniemi YA: Concordance for type1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia 1992; 35:1060-1067

30.            Nieminen MM, Kaprio J, Koskenvuo M: A population-based study of bronchial asthma in adult twin pairs. Chest 1991; 100:70-75

31.       Duffy DL, Martin NG, Battistutta D, al. e: Genetics of asthma and hay fever in Australian twins. American Review of Respiratory Diseases 1990; 142:1351-1358

32.       True WR, Xian H, Scherrer JF, Madden PAF, Bucholz KK, Heath AC, Eisen SA, Lyons MJ, Goldberg J, Tsuang MT: Common genetic vulnerability for nicotine and alcohol dependence in men. Archives of General Psychiatry 1999; 56:655-661

33.            Tsuang MT, Lyons MJ, Eisen S, al. e: Genetic influences on DSM-III-R drug abuse and dependence:  A study of 3,372 twin pairs. American Journal of Medical Genetics 1996; 67:473-477

34.            VandenBree M, Johnson E, Neale M, Pickens R: Genetic and environmental influences on drug use and abuse/dependence in male and female twins. Drug & Alcohol Dependence 1998; 52:231-241

35.            Kendler KS, Prescott C: Cannabis use, abuse and dependence in a population-based sample of female twins. American Journal of Psychiatry 1998; 155:1016-1022

36.            Nestler EJ: Molecular and cellular basis of addiction. Science 1997; 278:58-63

37.       Koob GF, Le Moal M: Drug abuse: Hedonic homeostatic regulation. Science 1997; 278:52-58

38.            Leshner AI: Addiction is a brain disease, and it matters. Science 1997; 278:45-47

39.       Koob GF, Bloom FE: Cellular and molecular mechanisms of drug dependence. Science 1998; 242:715-723

40.       Self DW, Nestler EJ: Molecular Mechanisms of Drug Reinforcement and Addiction. Annual Review of Neuroscience 1995; 18:463-495

41.       Ortiz J, Fitzgerald LW, Charlton M, Lane S, Trevisan L, Guitart X, Shoemaker W, Duman RS, Nestler EJ: Biochemical actions of chronic ethanol exposure in the mesolimbic dopamine system. Synapse 1995; 21(4):289-298

42.       Hymen SE: Addiction to cocaine and amphetamine. Neuron 1996; 16:901-904

43.            McLellan AT, Lewis DC, O'Brien CP, Kleber HD: Drug dependence, a chronic medical illness:  Implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284(13):1689-1695

44.            Childress AR, McLegin W, Mozley PD, al. e: Limbic activation during cue-induced cocaine craving. American Journal of Psychiatry 1999; 156:11-18

45.            Braxton DM, Kammerer CM, Blangero J, Mahaney MC, Rainwater DL, Dyke B, Hixson JE, Henkel RD, Sharp RM, Comuzzie AG, VandeBerg JL, Stern MP, MacCluer JW: Genetic and environmental contributions to cardiovascular risk factors in Mexican Americans:  The San Antonio Family Heart Study. Circulation 1996; 94:2159-2170

46.            Svetkey LP, McKeown SP, Wilson AF: Heritability of salt sensitivity in black Americans. Hypertension 1996; 28(5):854-858

47.            Schuckit MA, Smith TL: An 8-year follow-up of 450 sons of alcoholics and controls. Archives of General Psychiatry 1996; 53:202-210

48.            Schuckit MA: Low level of response to alcohol as a predictor of future alcoholism. American Journal of Psychiatry 1994; 151:184-189

49.       Chao YC, Kiou SR, Chung YY, Tang HS, Hsu CT, Li TK, Yin SJ: Polymorphism of alcohol and aldehyde dehydrogenase genese and alcoholic cirrhosis in Chinese patietns. Hepatology 1994; 19:360-366

50.            Thomasson HR, Edenberg HJ, Crabb DW, Mai XL, Jerome RE, Li TK, Wang SP, Lin YT, Lu RB, Yin SJ: Alcohol and aldehyde dehydrogenase genotypes and alcoholism in Chinese men. American Journal of Human Genetics 1991; 48:667-681

51.       Powers AC: Diabetes mellitus, in Harrison's Online: Harrison's Principles of Internal Medicine. Edited by Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Isselbacher KJ, McGraw-Hill Companies, Inc., 2005, p Chapter 323

52.            McFadden ERJ: Asthma, in Harrison's Online: Harrison's Principles of Internal Medicine. Edited by Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Isselbacher KJ, McGraw-Hill Companies, Inc., 2005, p Chapter 236

53.       Fisher NDL, Williams GH: Hypertensive Vascular Disease, in Harrison's Online: Harrison's Principles of Internal Medicine. Edited by Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Isselbacher KJ, McGraw-Hill Companies, Inc., 2005, p Chapter 230

54.            National Institute on Drug Abuse: Principles of drug addiction treatment: A research based guide. Bethesda, MD, National Institutes of Health, 1999

55.            Dekker FW, Dieleman FE, Kaptein AA, Mulder JD: Compliance with pulmonary medication in general practice. European Respiratory Journal 1993; 6:886-890

56.       Graber AL, Davidson P, Brown A, McRae J, Woolridge K: Drop out and relapse during diabetes care. Diabetes Care 1992; 15:1477-1483

57.            Cramer JA: A systematic review of adherence with medications for diabetes.[see comment]. [Review] [43 refs]. Diabetes Care 2004; 27(5):1218-1224

58.       Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD: Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999; 160:41–46

59.       Psaty BM, Koepsell TD, Yanez ND, al. e: Temporal patterns of antihypertensive medication use among older adults, 1989 through 1992: An effect of the major clinical trials on clinical practice? JAMA 1995; 273:1436–1438

60.       Clark LT: Improving compliance and increasing control of hypertension:  Needs of special hypertensive populations. American Heart Journal 1991; 121:664-669

61.       Kurtz SM: Adherence to diabetic regimens:  Empirical status and diabetic regimens. Diabetes Education 1990; 16:50-59

62.            Greenstein RA, Fudala PJ, O'Brien CP: Alternative pharmacotherapies for opiate addiction., in Comprehensive Textbook of Substance Abuse. Edited by Lowinsohn JH, Ruiz P, Millman RB, Langrod JG. New York, NY, Williams & Wilkins, 1997, pp 415-425

63.       Bouza C, Angeles M, Munoz A, Amate JM: Efficacy and safety of naltrexone and acamprasate in the treatment of alcohol dependence:  A systematic review. Addiction 2004; 99:811-828

64.       Chick J, Gough K, Wojciech F, Kershaw P, Hore B, Mehta B, Ritson B, Ropner R, Torley D: Disulfiram treatment of alcoholism. British Journal of Psychiatry 1992; 161:84-89

65.       Turner RC, Cull CA, Valeria F, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with Type II diabetes mellitus:  Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281(21):2005-2112

66.       Yurk RA, Diette GB, Skinner EA, Dominici F, Clark RD, Steinwachs DM, Wu AW: Predicting patient-reported asthma outcomes for adults in managed care. American Journal of Managed Care. 10(5):321-8, 2004 May. 2004

67.       Godley P, Pham H, Rohack J, Woodward B, Yokoyama K, Maue SK: Opportunities for improving the quality of hypertension care in a managed care setting. American Journal of Health-System Pharmacy. 58(18):1728-33, 2001 Sep 15. 2001

68.            Hubbard RL, Craddock SG, Flynn PM, Anderson J, Etheridge RM: Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychology of Addiction 1997; 11(4):261-278

69.       Booth RE, Crowley TJ, Zhang Y: Substance abuse treatment entry, retention and effectiveness. Drug & Alcohol Dependence 1996; 42:11-20

70.       Svikis DS, Golden AS, Huggins GR, al. e: Cost-effectiveness of treatment for drug abusing pregnant women. Drug & Alcohol Dependence 1997; 45:105-113

71.            Sinnock P: Hospitalization of diabetes, in Diabetes Data:  National Diabetes Data Group. Bethesda, MD, National Institutes of Health Press, 1985

72.            Lowinson J, Ruiz P, Millman RB (eds): Substance Abuse:  A Comprehensive Texbook. Baltimore, MD, Williams and Wilkins, 1992

73.            American Society of Addiction Medicine: Principles of Addiction Medicine. New York, NY, Harcourt Brace Press, 1999